Chai Discovery has launched Chai 2, a generative AI platform for antibody design that achieves a ~20% success rate in zero-shot discovery, a 100-200x improvement over previous computational methods.
This breakthrough signals a shift in drug development from a high-throughput screening 'discovery' process to a more predictable 'engineering' discipline, enabling the design of molecules with atomic precision.
Despite a significant downturn in the biotech market, the speakers are 'bullish on biotech', believing this technological leap will reduce costs, shorten timelines, and unlock novel therapeutics that were previously intractable.
Chai Discovery is opening access to its platform for academic and industry partners, aiming to make its state-of-the-art models a foundational tool for the entire drug development industry.
8 quotes
Concerns Raised
The broader biotech market is in a severe downturn due to macro-economic factors, creating a challenging capital environment.
Overcoming industry skepticism about the generalizability and real-world applicability of AI-designed drugs.
The high cost and complexity of debugging large-scale deep learning models, where a single bug can waste significant compute resources.
Opportunities Identified
Dramatically reducing the cost and timeline of antibody discovery, from millions of dollars over years to a fraction of that in weeks.
Tackling previously difficult or failed drug discovery projects by applying a new, more powerful design tool.
Expanding beyond monoclonal antibodies to design more complex, next-generation therapeutics like bi-paratopic antibodies.
Licensing the Chai 2 platform to industry and academic partners, creating a new revenue stream and establishing it as an industry standard.